Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity

Heather L. Kinkead, Elizabeth M. Jaffee, Eric R Lutz, Todd D. Armstrong

Research output: Chapter in Book/Report/Conference proceedingChapter


Cancer vaccines, in order to be successful, must generate tumor-specific CD8+ T cells that can effectively traffic to the tumor microenvironment (TME) and maintain their activity in the immunosuppressive TME. T cell avidity and priming are critical components of an effective vaccine response, but the immunosuppressive environment of the tumor may still inhibit optimal T cell function. The addition of immune checkpoint inhibitors to existing cancer vaccines has been associated with an effective T cell response that translates into prolonged survival. This article will examine the components necessary to induce a potent and effective CD8+ T cell response using combination vaccine immunotherapies.

Original languageEnglish (US)
Title of host publicationImmunity to Pathogens and Tumors
PublisherElsevier Inc.
Number of pages8
ISBN (Print)9780080921525
StatePublished - Apr 27 2016


  • Avidity
  • CD8 T cells
  • CTLA-4
  • Cyclophosphamide
  • GVAX
  • Immune checkpoint inhibitor
  • Immunotherapy
  • Listeria monocytogenes
  • OX40
  • PD-1
  • Tumor microenvironment
  • Vaccines

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity'. Together they form a unique fingerprint.

Cite this